MAR 14 2027
Takeda — zasocitinib $TAK
for adults with moderate-to-severe plaque psoriasis
Accepted SEP 14 2026.
About
Psoriasis is a long-lasting autoimmune condition in which the immune system mistakenly attacks the skin, producing raised, scaly patches that can itch, crack, and persist for years. Zasocitinib is a once-daily pill that blocks TYK2, a protein inside immune cells that helps drive the inflammation behind those patches, while largely sparing related proteins that cause unwanted side effects. By quieting this specific immune signal, the drug may ease scaling and itching for adults with moderate-to-severe plaque psoriasis.
Pivotal trial
The main aim of this study is to assess whether zasocitinib works better than deucravacitinib in treating participants with moderate-to-severe plaque psoriasis. Participants will take one tablet daily of either zasocitinib or a matching placebo, along with one capsule daily of either over-encapsulated deucravacitinib or a matching placebo, for a duration of 16 weeks
Source: ClinicalTrials.gov
Also in development
Drug Watch — recent news on zasocitinib
- Q&A: Zasocitinib Response in the Scalp, Nails, Palms and Soles - HCPLive
- Q&A: Zasocitinib's Role Beyond Topicals in Moderate to Severe Psoriasis - HCPLive
- Zasocitinib NDA Acceptance: What It Means for Psoriasis Treatment - HCPLive
- Takeda Pharmaceutical (TAK) Gets Priority Review. Can Zasocitinib Win in Psoriasis? - Yahoo Finance
- FDA Grants Priority Review to Zasocitinib for Moderate-to-Severe Psoriasis - Medscape